Zamin Raza is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice.
Prior to attending law school, Zamin conducted research under Dr. Walter Rowe at The George Washington University and worked as a chemist for the Department of Homeland Security, where he supported federal interdiction efforts by analyzing and interpreting chemical screening data. During law school, Zamin clerked at the U.S. Office of Special Counsel, Retaliation, and Disclosure Unit.
Zamin Raza is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice.
Prior to attending law school, Zamin conducted research under Dr. Walter Rowe at The George Washington University and worked as a chemist for the Department of Homeland Security, where he supported federal interdiction efforts by analyzing and interpreting chemical screening data. During law school, Zamin clerked at the U.S. Office of Special Counsel, Retaliation, and Disclosure Unit.
- J.D., The George Washington University Law School, 2023
Articles Editor, American Intellectual Property Law Association Journal; Justice, Student Association Court
- M.F.S., Forensic Chemistry, The George Washington University, 2018
- B.S., Chemistry and Political Science, The George Washington University, 2017
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
- J.D., The George Washington University Law School, 2023
Articles Editor, American Intellectual Property Law Association Journal; Justice, Student Association Court
- M.F.S., Forensic Chemistry, The George Washington University, 2018
- B.S., Chemistry and Political Science, The George Washington University, 2017
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
TMS and JIXING will form a collaborative partnership to globally develop TMS-007—a novel antithrombotic agent developed for the treatment of acute ischemic stroke (AIS)—with TMS regaining royalty-free Japan rights while JIXING will lead the development and commercialization of TMS-007 in the rest of the world. TMS and JIXING will join forces to expeditiously develop and launch TMS-007 globally, facilitated by the formation of a Joint Development Committee. In addition, TMS will receive an upfront payment of $5 million in the form of JIXING equity, up to $12.5 million in development milestones, up to $355 million in commercial milestones, and tiered royalties consistent with the original Option Agreement.
Concurrently, JIXING licenses to TMS exclusive Japan rights of JX09. JX09 is an oral, novel, small molecule ASI in development for the treatment of resistant and/or uncontrolled hypertension by JIXING, which is planned to enter into a first-in-human Phase 1 clinical trial in early 2024.
The Wilson Sonsini team that advised JIXING on the transactions included partners Michael Hostetler, Farah Gerdes, Mark Bellomy, Greg Broome, and Jen Fang; associates Zack Burns, TJ Tingjie Li, Ying Chen, Brandon King, Christina Fuleihan, Hee Min Noh, and Zamin Raza; and patent agent Jamie Gleason-Bremer.
For more information, please see the companies’ news release.
- Privacy Policy
- Terms of Use
- Accessibility